Last reviewed · How we verify
NCT07018869
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Phase 3 trial testing Intervention website access in Colorectal Cancer Stage II in 1,057 participants. Currently enrolling.
23 May 2029
Quick facts
| Lead sponsor | SWOG Cancer Research Network |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 1,057 |
| Start date | 15 October 2025 |
| Primary completion | 23 May 2029 |
| Estimated completion | 6 June 2029 |
| Sites | 384 locations across Guam, United States, Puerto Rico |
Drugs / interventions tested
- Intervention website access
- Control website access
- Interview
- Questionnaire Administration
Conditions studied
- Colorectal Cancer Stage II — all drugs for Colorectal Cancer Stage II →
- Colorectal Cancer Stage III — all drugs for Colorectal Cancer Stage III →
Sponsor
SWOG Cancer Research Network
Who can join
18 and older, any sex, with Colorectal Cancer Stage II or Colorectal Cancer Stage III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that aligns with current guidelines (guideline-concordant). Surveillance care after resection of colorectal cancer is critical to detect potentially curable return of disease (recurrence), yet up to 60% of colorectal cancer survivors fail to receive surveillance. This may be due to a lack of knowledge about the purpose of surveillance care and the risks of cancer recurrence, or a lack of confidence for managing surveillance care. The CTAC intervention is an online education intervention designed to improve patients' knowledge about surveillance and their self-efficacy for managing surveillance, and to promote effective communication with supporters and supporter engagement in patients' surveillance in a way that is aligned with each patient's preferences. By increasing a patient's knowledge, self-efficacy, and satisfaction with their supporter's engagement in their care, the CTAC intervention may increase the number of patients who receive guideline-concordant surveillance care after resection of colorectal cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07018869
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer Stage II
Currently open trials in the same condition.
- NCT06958926 — A Translational Study for Locoregional Recurrence of T4 Colon Cancer · recruiting
- NCT07226115 — Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer · recruiting
- NCT06076811 — DANISH.MRD: Danish Assessment of Minimal Residual Disease by Liquid Biopsies · recruiting
- NCT05898789 — Virtual Rehabilitation for Cancer Survivors · NA · recruiting
- NCT06342401 — Early Onset Colorectal Cancer Detection · recruiting
Other SWOG Cancer Research Network trials
Trials by the same sponsor.
- NCT07498205 — Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts · Phase 4 · not yet recruiting
- NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
- NCT07278739 — Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams · NA · not yet recruiting
- NCT06769126 — Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM · Phase 2 · recruiting
- NCT06616584 — Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07018869 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by SWOG Cancer Research Network
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07018869.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing